JP2004509914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004509914A5 JP2004509914A5 JP2002530042A JP2002530042A JP2004509914A5 JP 2004509914 A5 JP2004509914 A5 JP 2004509914A5 JP 2002530042 A JP2002530042 A JP 2002530042A JP 2002530042 A JP2002530042 A JP 2002530042A JP 2004509914 A5 JP2004509914 A5 JP 2004509914A5
- Authority
- JP
- Japan
- Prior art keywords
- surfactant
- polymer
- poly
- lactide
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000004094 surface-active agent Substances 0.000 description 66
- 239000000203 mixture Substances 0.000 description 53
- 238000000034 method Methods 0.000 description 44
- 229920000642 polymer Polymers 0.000 description 40
- 239000011859 microparticle Substances 0.000 description 26
- 239000000839 emulsion Substances 0.000 description 16
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 239000003093 cationic surfactant Substances 0.000 description 14
- 239000010419 fine particle Substances 0.000 description 12
- 108091033319 polynucleotide Proteins 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 8
- 229940061720 alpha hydroxy acid Drugs 0.000 description 8
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 8
- 229920002521 macromolecule Polymers 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 230000001804 emulsifying effect Effects 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- 239000007764 o/w emulsion Substances 0.000 description 5
- 229920001432 poly(L-lactide) Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 4
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229920002732 Polyanhydride Polymers 0.000 description 3
- 229920001710 Polyorthoester Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000003067 hemagglutinative effect Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 208000037797 influenza A Diseases 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000002745 poly(ortho ester) Substances 0.000 description 3
- 229920001610 polycaprolactone Polymers 0.000 description 3
- 239000004632 polycaprolactone Substances 0.000 description 3
- 229920002721 polycyanoacrylate Polymers 0.000 description 3
- -1 polynucleosides Proteins 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- MJWYCUZCRGLCBD-BGZMIMFDSA-N (4s)-4-amino-5-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(O)=O MJWYCUZCRGLCBD-BGZMIMFDSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical group O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 108010008118 glutamyl-leucyl-valyl-isoleucyl-serine Proteins 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23607700P | 2000-09-28 | 2000-09-28 | |
| PCT/US2001/030541 WO2002026212A2 (en) | 2000-09-28 | 2001-09-28 | Microparticle compositions and methods for the manufacture thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013098678A Division JP2013147514A (ja) | 2000-09-28 | 2013-05-08 | 微粒子組成物およびその製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004509914A JP2004509914A (ja) | 2004-04-02 |
| JP2004509914A5 true JP2004509914A5 (enExample) | 2012-09-06 |
Family
ID=22888043
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002530042A Withdrawn JP2004509914A (ja) | 2000-09-28 | 2001-09-28 | 微粒子組成物およびその製造方法 |
| JP2013098678A Pending JP2013147514A (ja) | 2000-09-28 | 2013-05-08 | 微粒子組成物およびその製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013098678A Pending JP2013147514A (ja) | 2000-09-28 | 2013-05-08 | 微粒子組成物およびその製造方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US6753015B2 (enExample) |
| EP (1) | EP1322292B1 (enExample) |
| JP (2) | JP2004509914A (enExample) |
| CN (2) | CN101428006A (enExample) |
| AT (1) | ATE350015T1 (enExample) |
| AU (2) | AU9489801A (enExample) |
| BR (1) | BR0114304A (enExample) |
| CA (1) | CA2420621C (enExample) |
| DE (1) | DE60125795T2 (enExample) |
| ES (1) | ES2278786T3 (enExample) |
| MX (1) | MXPA03002643A (enExample) |
| RU (1) | RU2257198C2 (enExample) |
| WO (1) | WO2002026212A2 (enExample) |
| ZA (1) | ZA200301743B (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6884435B1 (en) * | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| ES2195317T3 (es) * | 1997-01-30 | 2003-12-01 | Chiron Corp | Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias. |
| AU2457100A (en) * | 1999-02-26 | 2000-09-14 | Chiron S.P.A. | Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs |
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| EP1240331B1 (en) * | 1999-12-22 | 2010-04-07 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| WO2001051500A1 (en) | 2000-01-14 | 2001-07-19 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| US20030138453A1 (en) * | 2000-09-28 | 2003-07-24 | O'hagan Derek | Microparticles for delivery of heterologous nucleic acids |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| AU2002322358B2 (en) * | 2001-06-29 | 2009-06-18 | Novartis Vaccines And Diagnostics, Inc. | HCV E1E2 vaccine compositions |
| US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
| US7354909B2 (en) * | 2001-08-14 | 2008-04-08 | The United States Of America As Represented By Secretary Of The Department Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
| AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
| JP4646516B2 (ja) * | 2002-02-20 | 2011-03-09 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 吸着したポリペプチド含有分子を有する微粒子 |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| US20040115254A1 (en) * | 2002-09-06 | 2004-06-17 | Genteric, Inc. | Microcapsules and methods of use |
| US8263091B2 (en) | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
| WO2004032860A2 (en) | 2002-10-07 | 2004-04-22 | Chiron Corporation | Hiv vaccine formulations |
| CA2506318C (en) | 2002-11-15 | 2011-07-12 | Chiron Srl | Unexpected surface proteins in neisseria meningitidis |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| EP2263687B1 (en) | 2002-12-27 | 2015-03-25 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions containing phospholipid |
| US20050191358A1 (en) * | 2003-01-14 | 2005-09-01 | Derek O' Hagan | Microparticles with adsorbed polynucleotide-containing species |
| GB0300881D0 (en) * | 2003-01-15 | 2003-02-12 | Secr Defence | Therapeutic treatment |
| AU2004224746B2 (en) * | 2003-03-24 | 2009-04-23 | Valneva Austria Gmbh | Improved vaccines |
| WO2004096136A2 (en) * | 2003-04-25 | 2004-11-11 | Chiron Corporation | Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof |
| ES2596553T3 (es) | 2003-06-02 | 2017-01-10 | Glaxosmithkline Biologicals Sa | Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido |
| GB2407500A (en) * | 2003-11-03 | 2005-05-04 | Ist Superiore Sanita | Use of microparticles for antigen delivery |
| US7682009B1 (en) * | 2004-06-01 | 2010-03-23 | Sliwa Jr John W | Cooling, condensation and freezing of atmospheric water or of a microfluidic working-material in or on microfluidic devices |
| AU2005334819B2 (en) * | 2004-11-15 | 2011-11-24 | Novartis Vaccines And Diagnostics Inc. | Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant |
| JP2006169336A (ja) * | 2004-12-15 | 2006-06-29 | Nissan Motor Co Ltd | 情報化核酸含有透明樹脂組成物 |
| JP2006169337A (ja) * | 2004-12-15 | 2006-06-29 | Nissan Motor Co Ltd | 不透明樹脂組成物 |
| BRPI0614254A2 (pt) * | 2005-08-02 | 2011-03-15 | Novartis Vaccines & Diagnostic | redução de interferência entre adjuvantes contendo óleo e antìgenos contendo tensoativos |
| US9393215B2 (en) * | 2005-12-02 | 2016-07-19 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
| RU2327170C2 (ru) * | 2006-02-27 | 2008-06-20 | Закрытое акционерное общество "ДиТест" | Способ комплексной диагностики вирусного гепатита в, вирусного гепатита с, вич-инфекции и сифилиса |
| RU2326655C1 (ru) * | 2006-11-09 | 2008-06-20 | Федеральное государственное учреждение "48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации" | Способ инкапсулирования белоксодержащих веществ в микросферы из сополимера полилактид-полигликолид |
| JP5668476B2 (ja) | 2007-10-08 | 2015-02-12 | オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物 |
| WO2009134769A1 (en) * | 2008-04-28 | 2009-11-05 | Novartis Ag | Nanoparticles for use in pharmaceutical compositions |
| RU2392668C1 (ru) * | 2008-12-15 | 2010-06-20 | Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" | Способ индукции антипролиферативного, цитотоксического эффекта в опухолевых клетках линейных и свежевыделенных культур |
| EP2440185B1 (en) | 2009-06-09 | 2015-04-08 | Aurinia Pharmaceuticals Inc. | Topical drug delivery systems for ophthalmic use |
| RU2413311C1 (ru) * | 2009-07-29 | 2011-02-27 | Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" | Способ индукции антипролиферативного действия в эксперименте |
| EP2525815B1 (en) * | 2010-01-24 | 2015-02-25 | Novartis AG | Irradiated biodegradable polymer microparticles |
| WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| EP2555798B1 (en) * | 2010-04-09 | 2016-06-22 | Reef Pharmaceuticals Pty Ltd | Methods and compositions for inhibiting hiv transmission |
| CA2804591C (en) | 2010-07-06 | 2019-01-22 | Novartis Ag | Cationic oil-in-water emulsions |
| ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
| US9655845B2 (en) | 2011-07-06 | 2017-05-23 | Glaxosmithkline Biologicals, S.A. | Oil-in-water emulsions that contain nucleic acids |
| AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
| US20140105970A1 (en) * | 2011-12-01 | 2014-04-17 | Flow Pharma, Inc. | Adjuvant and antigen particle formulation |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| CA2932532C (en) | 2012-12-04 | 2021-06-22 | Phosphorex, Inc. | Microparticles and nanoparticles having negative surface charges |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| JP6671300B2 (ja) * | 2014-05-27 | 2020-03-25 | アーティフィシャル セル テクノロジーズ インコーポレイテッド | Ｔｆｆによる多層コーティング化コアの自動交互積層構築 |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| CN114617959A (zh) | 2015-09-03 | 2022-06-14 | 诺瓦瓦克斯股份有限公司 | 具有改进的稳定性和免疫原性的疫苗组合物 |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| BR112020000506A2 (pt) | 2017-07-11 | 2020-07-14 | Sustained Nano Systems Llc | formulações farmacêuticas hipercomprimidas |
| EP3461857A1 (en) * | 2017-09-28 | 2019-04-03 | Helmholtz-Zentrum Geesthacht Zentrum für Material- und Küstenforschung GmbH | Surface-functionalised polymeric object and method of its production |
| US12220486B2 (en) | 2018-03-02 | 2025-02-11 | Saint Joseph's University | Polymer compositions for storage and release of polypeptides |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE634667A (enExample) | 1962-07-11 | |||
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| GB9211268D0 (en) * | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| FR2695563B1 (fr) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
| PL174772B1 (pl) * | 1993-01-06 | 1998-09-30 | Kinerton Ltd | Kompozycja farmaceutyczna zawierająca jonowy konjugat cząsteczkowy |
| DE69418699T2 (de) | 1993-01-11 | 1999-09-30 | Dana-Farber Cancer Institute, Boston | Induktion der antworten zytotoxischer t-lymphozyten |
| GB9311454D0 (en) | 1993-06-03 | 1993-07-21 | Agricultural & Food Res | Pharmaceutical compositions |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| US5643605A (en) * | 1993-10-25 | 1997-07-01 | Genentech, Inc. | Methods and compositions for microencapsulation of adjuvants |
| EP0804249A2 (en) | 1994-03-15 | 1997-11-05 | Brown University Research Foundation | Polymeric gene delivery system |
| GB9412273D0 (en) | 1994-06-18 | 1994-08-10 | Univ Nottingham | Administration means |
| ATE252894T1 (de) * | 1995-01-05 | 2003-11-15 | Univ Michigan | Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung |
| GB9514285D0 (en) | 1995-07-13 | 1995-09-13 | Univ Nottingham | Polymeric lamellar substrate particles for drug delivery |
| JPH09255590A (ja) * | 1996-03-21 | 1997-09-30 | Japan Synthetic Rubber Co Ltd | 徐放性薬剤 |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| ES2301178T3 (es) | 1996-04-05 | 2008-06-16 | Novartis Vaccines & Diagnostic | Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular. |
| GB9619002D0 (en) | 1996-09-11 | 1996-10-23 | Oxford Biosciences Ltd | Particle delivery |
| US6491925B2 (en) * | 1996-08-15 | 2002-12-10 | Emory University | Compositions and methods for cancer prophylaxis and/or treatment |
| US5842723A (en) | 1996-11-25 | 1998-12-01 | Burex Automotive America, Inc. | Flexible connection arrangement for connecting a pipe of an exhaust system to an engine, especially in a motor vehicle |
| US5783567A (en) | 1997-01-22 | 1998-07-21 | Pangaea Pharmaceuticals, Inc. | Microparticles for delivery of nucleic acid |
| ES2195317T3 (es) | 1997-01-30 | 2003-12-01 | Chiron Corp | Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias. |
| WO2000006123A1 (en) * | 1998-07-29 | 2000-02-10 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| US5840970A (en) * | 1997-10-03 | 1998-11-24 | Eastman Chemical Company | Process for the purification of naphthalenedicarboxylic acid |
| PT1042001E (pt) | 1997-12-16 | 2002-09-30 | Chiron Corp | Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua |
| US6395253B2 (en) * | 1998-04-23 | 2002-05-28 | The Regents Of The University Of Michigan | Microspheres containing condensed polyanionic bioactive agents and methods for their production |
| WO2000050006A2 (en) | 1999-02-26 | 2000-08-31 | Chiron Corporation | Microemulsions with adsorbed macromoelecules and microparticles |
| US20020009466A1 (en) * | 1999-08-31 | 2002-01-24 | David J. Brayden | Oral vaccine compositions |
| ES2411096T3 (es) * | 1999-10-27 | 2013-07-04 | Novartis Vaccines And Diagnostics, Inc. | Activación de linfocitos T específicos contra el VHC |
| WO2001036599A1 (en) | 1999-11-19 | 2001-05-25 | Chiron Corporation | Microparticle-based transfection and activation of dendritic cells |
| US20010046967A1 (en) * | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
| WO2001081609A2 (en) | 2000-03-22 | 2001-11-01 | Chiron Corporation | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
-
2001
- 2001-09-28 WO PCT/US2001/030541 patent/WO2002026212A2/en not_active Ceased
- 2001-09-28 ES ES01975585T patent/ES2278786T3/es not_active Expired - Lifetime
- 2001-09-28 BR BR0114304-2A patent/BR0114304A/pt not_active Application Discontinuation
- 2001-09-28 RU RU2003112239/15A patent/RU2257198C2/ru not_active IP Right Cessation
- 2001-09-28 AT AT01975585T patent/ATE350015T1/de active
- 2001-09-28 MX MXPA03002643A patent/MXPA03002643A/es active IP Right Grant
- 2001-09-28 DE DE60125795T patent/DE60125795T2/de not_active Expired - Lifetime
- 2001-09-28 AU AU9489801A patent/AU9489801A/xx active Pending
- 2001-09-28 US US09/967,462 patent/US6753015B2/en not_active Expired - Lifetime
- 2001-09-28 CN CNA2008101750512A patent/CN101428006A/zh active Pending
- 2001-09-28 AU AU2001294898A patent/AU2001294898B2/en not_active Ceased
- 2001-09-28 CN CNA018165575A patent/CN1535140A/zh active Pending
- 2001-09-28 EP EP01975585A patent/EP1322292B1/en not_active Expired - Lifetime
- 2001-09-28 JP JP2002530042A patent/JP2004509914A/ja not_active Withdrawn
- 2001-09-28 CA CA2420621A patent/CA2420621C/en not_active Expired - Fee Related
-
2003
- 2003-03-03 ZA ZA200301743A patent/ZA200301743B/en unknown
-
2004
- 2004-02-10 US US10/775,964 patent/US7846479B2/en not_active Expired - Fee Related
-
2013
- 2013-05-08 JP JP2013098678A patent/JP2013147514A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2420621A1 (en) | Microparticle compositions and methods for the manufacture thereof | |
| JP6407208B2 (ja) | 合成ナノキャリア混合ワクチン | |
| JP5502751B2 (ja) | 低残留溶媒濃度を有する微粒子を調製するためのプロセス | |
| JP2002521425A5 (enExample) | ||
| JP5841565B2 (ja) | 残留溶媒抽出方法および同により生成される微粒子 | |
| RU2003112239A (ru) | Композиции микрочастиц и способы их получения | |
| EP2142216B1 (en) | Particle formulations and uses thereof | |
| JP2004518631A5 (enExample) | ||
| JP2014080442A (ja) | リン脂質を含む免疫原性組成物 | |
| AU2001294898A1 (en) | Microparticle compositions and methods for the manufacture thereof | |
| JP2002521425A (ja) | 吸着表面を有する微小粒子、それを作製する方法、およびその使用 | |
| JP2003511420A5 (enExample) | ||
| JP2007507527A5 (enExample) | ||
| JP2002508334A5 (enExample) | ||
| JP2006520746A5 (enExample) | ||
| Mao et al. | Recent advances in polymeric microspheres for parenteral drug delivery—part 2 | |
| Hou et al. | Up-to-date vaccine delivery systems: robust immunity elicited by multifarious nanomaterials upon administration through diverse routes | |
| JP2007509902A5 (enExample) | ||
| US20220331259A1 (en) | Biodegradable polymeric particles encapsulating an active agent, pharmaceutical compositions and uses thereof | |
| US20200054571A1 (en) | Formulation for protection through controlled release of microparticles containing recombinant outer membrane vesicles | |
| JP2005526697A (ja) | アジュバント化されたＭｅｎｉｎｇｏｃｏｃｃｕｓ組成物 | |
| Zhang et al. | Polymer–protein core–shell nanoparticles for enhanced antigen immunogenicity | |
| Fu | Current landscape and challenges in adjuvant and antigen delivery systems for vaccine | |
| Slomkowski et al. | Progress in nanoparticulate systems for peptide, proteins and nucleic acid drug delivery | |
| JP2008207137A (ja) | 異なる平均粒径サイズの粒子からなる混合微粒子カプセルの製造方法 |